Novel Peptide Senolytic Agent Reverses Brain Aging and Cognitive Decline in Mice

Cellular senescence, a state where cells stop dividing but remain metabolically active and secrete pro-inflammatory factors, is a major contributor to brain aging and cognitive decline. These senescent cells accumulate in the brain, leading to neuroinflammation and neuronal dysfunction. While senolytics (drugs that selectively kill senescent cells) show promise, a specific pharmacological strategy to target the FOXO4-p53 axis, a critical pathway involved in senescent cell survival, for brain health has been lacking.

Treatment with Senolytin-P1 significantly improved cognitive performance in aged mice. In the Morris Water Maze, treated mice showed a 45% reduction in escape latency and a 38% increase in time spent in the target quadrant compared to vehicle-treated controls (p<0.001). Brain tissue analysis revealed a dramatic decrease in senescent cell burden; specifically, p16INK4a positive cells in the hippocampus were reduced by 70% (p<0.0001). Senolytin-P1 treatment led to a significant reversal of age-related cognitive deficits and a robust reduction in senescent cell accumulation in the brain, demonstrating a profound neuroprotective effect. Furthermore, neuroinflammation was substantially mitigated, with GFAP (a marker for astrocyte activation) levels decreasing by 55% and Iba1 (a marker for microglial activation) by 60% in the treated group (p<0.01). The study confirmed that Senolytin-P1 specifically disrupted the interaction between FOXO4 and p53, promoting the selective apoptosis of senescent cells.